PRGO - Perrigo Company plc

NYSE - NYSE Delayed Price. Currency in USD
49.56
+0.59 (+1.20%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close48.97
Open48.67
Bid49.56 x 800
Ask0.00 x 1000
Day's Range48.00 - 49.97
52 Week Range36.28 - 82.85
Volume1,258,232
Avg. Volume1,249,412
Market Cap6.734B
Beta (3Y Monthly)2.00
PE Ratio (TTM)52.17
EPS (TTM)0.95
Earnings DateMay 6, 2019 - May 10, 2019
Forward Dividend & Yield0.76 (1.58%)
Ex-Dividend Date2019-02-28
1y Target Est58.80
Trade prices are not sourced from all markets
  • Can Core Renal Care Unit Drive Baxter's (BAX) Q1 Earnings?
    Zacks16 hours ago

    Can Core Renal Care Unit Drive Baxter's (BAX) Q1 Earnings?

    Strong performance across Renal Care, Clinical Nutrition, Advanced Surgery and Acute Therapies businesses might aid Baxter (BAX) in Q1. However, lower sales at Pharmaceutical business might be a woe.

  • 3 Medical Product Stocks Set to Beat This Earnings Season
    Zacks16 hours ago

    3 Medical Product Stocks Set to Beat This Earnings Season

    The global medical device space takes significant strides in terms of research and development (R&D) and regulatory progress in the first quarter.

  • A Closer Look At Perrigo Company plc's (NYSE:PRGO) Uninspiring ROE
    Simply Wall St.3 days ago

    A Closer Look At Perrigo Company plc's (NYSE:PRGO) Uninspiring ROE

    One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use Return On Equity (ROE) to better understand a business. We'll use ROE to examine Perri...

  • Perrigo To Host Investor Day
    PR Newswire5 days ago

    Perrigo To Host Investor Day

    The event will feature presentations from Murray S. Kessler, President and Chief Executive Officer, as well as members of the Company's leadership team. Perrigo Company is dedicated to making lives better by bringing "Quality, Affordable Self-care Products™" that consumers trust everywhere they are sold.  The Company is a leading provider of over-the-counter health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed.  Visit Perrigo online at (http://www.perrigo.com). Certain statements in this press release are "forward-looking statements." These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements.

  • Bloomberg20 days ago

    Apollo, CVC Are Vying for Perrigo's Pharmaceuticals Unit

    Carlyle Group LP, Altaris Capital Partners LLC and Cerberus Capital Management have also advanced to the next round of bidding for Perrigo’s Generic Rx unit, said the people, who asked to not be identified because the matter is private. Representatives for Apollo, CVC, Carlyle, Cerberus and Perrigo declined to comment.

  • Perrigo Announces Tentative FDA Approval For The Generic Version Of Sernivo® Spray, 0.05%
    PR Newswire20 days ago

    Perrigo Announces Tentative FDA Approval For The Generic Version Of Sernivo® Spray, 0.05%

    TASE: PRGO), a leading global provider of "Quality, Affordable, Self-Care Products™", today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Sernivo® (betamethasone dipropionate) Spray 0.05%. Perrigo previously settled its Hatch-Waxman litigation relating to Sernivo® (betamethasone dipropionate) Spray 0.05% brought by Promius Pharma LLC. Terms of the settlement remain confidential. Perrigo Executive Vice President and President Rx Pharmaceuticals Sharon Kochan stated, "Today's announcement marks our second tentative approval this year, in addition to four previously approved abbreviated new drug applications received in 2019.

  • Perrigo Announces Patent Litigation Settlement For The Generic Version Of Finacea® Foam, 15%
    PR Newswire22 days ago

    Perrigo Announces Patent Litigation Settlement For The Generic Version Of Finacea® Foam, 15%

    Perrigo Executive Vice President and President Rx Pharmaceuticals Sharon Kochan stated, "This settlement is another example of our long-term commitment and investments in our extended topicals strategy. Perrigo Company is dedicated to making lives better by bringing high "Quality, Affordable Self-care Products™" that consumers trust everywhere they are sold.  The Company is a leading provider of over-the-counter health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed.  Visit Perrigo online at (http://www.perrigo.com). Certain statements in this press release are "forward-looking statements." These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements.

  • Why Perrigo Company plc’s (NYSE:PRGO) High P/E Ratio Isn’t Necessarily A Bad Thing
    Simply Wall St.29 days ago

    Why Perrigo Company plc’s (NYSE:PRGO) High P/E Ratio Isn’t Necessarily A Bad Thing

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! This article is written for those who want to getRead More...

  • GlobeNewswirelast month

    Sol-Gel Technologies Reports Full Year 2018 Financial Results and Provides Corporate Update

    Company met all milestones in 2018 and this year expects to report Phase III top-line results for Epsolay® and TWIN, potentially best-in-class papulopustular rosacea and acne.

  • Perrigo Appoints Seasoned CPG Veteran Ray Silcock As Chief Financial Officer
    PR Newswirelast month

    Perrigo Appoints Seasoned CPG Veteran Ray Silcock As Chief Financial Officer

    TASE: PRGO) today announced that Ray Silcock will join the Company as Executive Vice President and Chief Financial Officer, effective March 25, 2019. Ray will lead the global finance, tax, internal audit, investor relations, corporate communications, business development and treasury functions. Mr. Silcock joins Perrigo having been CFO of both public and private equity held companies for over 20 years.

  • Perrigo Announces Tentative FDA Approval For The Generic Version Of Finacea® Foam, 15%
    PR Newswirelast month

    Perrigo Announces Tentative FDA Approval For The Generic Version Of Finacea® Foam, 15%

    DUBLIN , March 18, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) a leading global provider of "Quality, Affordable, Self-Care Products™" today announced it has received tentative approval ...

  • Markitlast month

    See what the IHS Markit Score report has to say about Perrigo Company PLC.

    Perrigo Company PLC NYSE:PRGOView full report here! Summary * Bearish sentiment is moderate Bearish sentimentShort interest | NeutralShort interest is moderate for PRGO with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold PRGO had net inflows of $2.80 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • GlobeNewswire2 months ago

    Recent Analysis Shows Veeva, Mobile TeleSystems OJSC, Jacobs Engineering Group, Perrigo Company plc, AstraZeneca, and Primoris Services Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, March 07, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Perrigo Confirms Patent Challenge for Generic Version of Nascobal®
    PR Newswire2 months ago

    Perrigo Confirms Patent Challenge for Generic Version of Nascobal®

    TASE) today announced that Endo Pharmaceuticals Inc. initiated patent litigation on March 1, 2019 in the United States District Court for the District of Delaware regarding Perrigo's Paragraph IV Abbreviated New Drug Application for cyanocobalamin nasal spray 500mcg, asserting patents listed in the Orange Book for Nascobal®. Perrigo Executive Vice President and President Rx Pharmaceuticals Sharon Kochan stated, "This ANDA filling and subsequent patent challenge further demonstrates our commitment to enhance our pipeline and product offering in the extended topical space. Perrigo Company is dedicated to making lives better by bringing high "Quality, Affordable Self-care Products™" that consumers trust everywhere they are sold. The Company is a leading provider of over-the-counter health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Visit Perrigo online at (http://www.perrigo.com).

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of PRGO earnings conference call or presentation 27-Feb-19 9:30pm GMT

    Q4 2018 Perrigo Company PLC Earnings Call

  • ACCESSWIRE2 months ago

    Final Deadline - Perrigo Company plc (PRGO) Bronstein, Gewirtz & Grossman, LLC

    NEW YORK, NY / ACCESSWIRE / March 4, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors with losses exceeding $25K that a class action lawsuit has been filed against Perrigo Company plc ("Perrigo" ...

  • GlobeNewswire2 months ago

    DEADLINE TODAY: UPDATE for YRCW, PRGO and YRIV: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

    NEW YORK, March 04, 2019 -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies..

  • ACCESSWIRE2 months ago

    Final Deadline Alert - Perrigo Company plc (PRGO) Bronstein, Gewirtz & Grossman, LLC

    NEW YORK, NY / ACCESSWIRE / March 3, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors with losses exceeding $25K that a class action lawsuit has been filed against Perrigo Company plc ("Perrigo" ...

  • ACCESSWIRE2 months ago

    DEADLINE ALERT - YRCW, PRGO & CNTF - - Bronstein, Gewirtz & Grossman, LLC

    NEW YORK, NY / ACCESSWIRE / March 3, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed againstthe following publicly-traded companies. You can review ...

  • Business Wire2 months ago

    PERRIGO INVESTOR ALERT: Rosen Law Firm Reminds Perrigo Company plc Investors of Important March 4, 2019 Deadline in Securities Class Action Lawsuit – PRGO

    Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Perrigo Company plc from November 8, 2018 through December 20, 2018, inclusive of the important March 4, 2019 deadline in the securities class action lawsuit filed against the company.

  • GlobeNewswire2 months ago

    SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Perrigo Company plc - March 4 Deadline – PRGO

    Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Perrigo Company plc (PRGO) from November 8, 2018 through December 20, 2018, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Perrigo investors under the federal securities laws. To join the Perrigo class action, go to http://pawarlawgroup.com/cases/perrigo-company-plc/ or call Vik Pawar, Esq.

  • GlobeNewswire2 months ago

    SHAREHOLDER ALERT: DNKEY YRCW SOGO PRGO: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

    NEW YORK, March 01, 2019 -- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a.

  • ACCESSWIRE2 months ago

    Perrigo Company plc (PRGO) Bronstein, Gewirtz & Grossman, LLC Class Action Update and Deadline -- March 4, 2019

    NEW YORK, NY / ACCESSWIRE / February 28, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Perrigo Company plc ("Perrigo" or the "Company") ...

  • ACCESSWIRE2 months ago

    Perrigo Company plc (PRGO) Bronstein, Gewirtz & Grossman, LLC Class Action Update & Lead Plaintiff Deadline -- March 4, 2019

    NEW YORK, NY / ACCESSWIRE / February 28, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Perrigo Company plc ("Perrigo" or the "Company") ...

  • GlobeNewswire2 months ago

    The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of YRCW, PRGO, AVEO and CVS

    NEW YORK, Feb. 28, 2019 -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a.